23andMe Holding Co.（ME）資訊與事件

$0.606

-0.129 (-21.26%)收盤時

ME 資訊

9.006-04Yahoo Finance

23andMe seeks new bids after $305 million offer from its co-founder

9.004-02TipRanks

Blockchain Projects Race to Rescue DNA Data as 23andMe Declares Bankruptcy

6.503-28NASDAQ.COM

How to Tune Out Market Noise

9.003-26Newsfilter

23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law

9.003-26CNBC

23andMe co-founder lashes out at CEO Wojcicki after bankruptcy filing, says board lacked oversight

6.503-26Benzinga

Cybersecurity Stocks To Outperform, It's The 'One Line Item That No Company In The World Is Cutting': Josh Brown

9.003-25Benzinga

23andMe's Bankruptcy Sparks Privacy Concerns Over Genetic Database Of 15 Million Customers

9.003-25CNBC

With 23andMe entering bankruptcy, here's how to delete your genetic data

9.003-25SeekingAlpha

23andMe bankruptcy sparks concerns over data privacy

4.503-25Benzinga

US Stocks Likely To Open Lower After 2-Day Advance: Clear And Measured Tariff Plan Could 'Trigger A Strong Relief Rally,' Says Expert

查看更多資訊

ME 事件

6/30 08:02

23andMe receives court approval for sale to TTAM Research Institute

23andMe Holding received approval from the U.S. Bankruptcy Court for the Eastern District of Missouri for the sale of substantially all of the Company's assets and ongoing business operations to TTAM Research Institute, a nonprofit public benefit corporation based in California and led by 23andMe Co-Founder and former CEO Anne Wojcicki. The transaction is expected to close in the coming weeks, subject to customary closing conditions. Under the terms of the agreement, TTAM will acquire substantially all of the assets of 23andMe, including the Personal Genome Service and Research Services business lines and the Lemonaid Health business, for a purchase price of $305M.

6/11 05:47

27 states, DC, sue 23andMe over sale of DNA data, NY Times reports

Genetic testing company 23andMe (ME) is being sued by 27 states and Washington, DC to oppose the sale of DNA data from its customers without their direct consent, The New York Times' Rylee Kirk reports. The suit, filed on Monday in U.S. Bankruptcy Court in the Eastern District of Missouri, argues that 23andMe needs to have permission from each and every customer before their data is potentially sold and that the information for sale "comprises an unprecedented compilation of highly sensitive and immutable personal data of consumers." 23andMe filed for bankruptcy in March, and is poised to be acquired by Regeneron Pharmaceuticals (REGN) for $256M, the lawsuit notes.

6/6 05:44

23andMe to hold second auction for DNA data, Bloomberg reports

23andMe (ME) will hold a second auction for its cache of DNA data with an opening bid of $305M from a group led by the company's former CEO, Anne Wojcicki, Bloomberg's Steven Church reports. The new auction is a compromise between Wojcicki, Regeneron (REGN), and 23andMe, with Wojcicki's group making the opening bid and Regeneron able to counter with an offer of at least $315M. The auction is part of 23andMe's bankruptcy proceedings, which began in March after the company failed to generate sustainable profits from its genetic testing services.

5/27 12:48

23andMe announces intent to voluntarily delist from Nasdaq, deregister with SEC

23andMe announced its intention to file a Form 25 Notification of Delisting with the Securities and Exchange Commission on or about June 6 which will remove its securities from listing and registration on Nasdaq. Nasdaq previously suspended the trading of 23andMe's Class A common stock at the opening of business on March 31 and notified the company that a Form 25 would be filed. However, as Nasdaq has not yet made the filing, the company is doing so voluntarily to permit it to file a Form 15 to deregister with the SEC. 23andMe previously announced on March 23 that the company and certain of its subsidiaries initiated voluntary Chapter 11 proceedings in the U.S. Bankruptcy Court for the Eastern District of Missouri. Once the Nasdaq delisting on Form 25 becomes effective, 23andMe intends to file a Form 15 to deregister with the SEC.

5/19 07:10

Regeneron enters asset purchase agreement to acquire 23andMe for $256M

Regeneron has been named the successful bidder in the bankruptcy auction for substantially all of the assets of 23andMe Holding. Regeneron intends to acquire 23andMe's Personal Genome Service, Total Health and Research Services business lines, together with its Biobank and associated assets, for $256M and for 23andMe to continue all consumer genome services uninterrupted. Subject to bankruptcy court and regulatory approvals and other customary closing conditions, the transaction is expected to close in the third quarter of 2025. Regeneron intends to ensure compliance with 23andMe's consumer privacy policies and applicable laws with respect to the treatment of customer data. As the successful bidder, Regeneron is prepared to detail the intended use of customer data and the privacy programs and security controls in place for review by a court-appointed, independent Customer Privacy Ombudsman and other interested parties. 23andMe will be operated as a wholly owned direct or indirect subsidiary of Regeneron Pharmaceuticals, Inc. and continue operations as a personal genomics service. Regeneron's purchase does not include 23andMe's Lemonaid Health business. Additional details about the company's operating plans will be shared at time of closing.

查看更多事件

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。